Every material Form 8-K Absci Corp has filed with the SEC since June 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Absci reported second-quarter 2026 results with revenue of $0.3 million, down from $0.6 million a year earlier, and a net loss of $33.2 million, up from $30.6 million. The company said its cash, cash equivalents, and marketable securities of $201.1 million, which include $93.6 million of net offering proceeds, are now expected to fund operations into the second half of 2028, which lessens near-term funding pressure for shareholders.
Revenue was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier.
Net loss was $33.2 million, or $0.21 per share, compared with $30.6 million, or $0.24 per share, a year earlier.
Completed a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company.
Cash and marketable securities were $201.1 million as of June 30, 2026, versus $125.7 million as of March 31, 2026.
Absci Corporation agreed to sell 13,495,277 common shares at $7.41 each, with gross proceeds expected to be about $100 million and estimated net proceeds of about $93.5 million. The company plans to use the money to advance ABS-201 for androgenetic alopecia and endometriosis and for working capital and general corporate purposes, and the offering is expected to close on June 25, 2026. The sale adds new shares outstanding, which dilutes existing holders, and Eli Lilly & Company is among the participating investors.
13,495,277 shares priced at $7.41 per share, with gross proceeds of about $100 million
Estimated net proceeds of about $93.5 million after underwriting discounts and offering expenses
Proceeds earmarked for ABS-201 in androgenetic alopecia and endometriosis, plus working capital
Expected closing on or about June 25, 2026; sold under an S-3 shelf effective August 22, 2025
Absci reported interim blinded Phase 1 data for ABS-201, an investigational antibody for androgenetic alopecia, showing study drug appeared well tolerated across 32 participants in four single ascending dose cohorts as of a June 8, 2026 data cutoff. The estimated half-life of at least 65 days is preliminary and supports a possible dosing schedule of two or three injections over six months, pending further follow-up. The filing contains no financial results or guidance, and the company expects interim proof-of-concept data in the second half of 2026.
Interim data covers 32 healthy adult participants across four single ascending dose cohorts, with a June 8, 2026 data cutoff
No serious adverse events reported as of the cutoff; treatment-related adverse events were reported in 5 participants and all were mild
Estimated half-life for ABS-201 is at least 65 days, pending confirmation through continued follow-up
Interim proof-of-concept data expected in the second half of 2026; full proof-of-concept data expected in early 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Absci Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →